iiinova — where your digital self keeps evolving

Ruben Sebastian @rubensebas.bsky.social · 17/12/2025

Great time celebrating the holidays at the New York Stock Exchange last night. It was a pleasure to join many colleagues from the #biotech finance & business communities on the iconic NYSE floor. I’m gradually becoming a true New Yorker! Happy holidays everyone! 🥂✨

000

Ruben Sebastian @rubensebas.bsky.social · 08/12/2025

Great news reported today from two of my #portfolio companies: $KYMR (+107% over the last 6 months) and $DYN (+63% same period). Stocks are trading well on strong clinical redouts, with public markets now rewarding good data. You can own stocks into clinical catalysts and be compensated for it

200

Ruben Sebastian @rubensebas.bsky.social · 06/10/2025

Great recognition to a fundamental discovery that reshaped modern #immunology. Congrats to the laureates! However, imho the Nobel committee missed the chance to acknowledge an additional key contributor to the understanding of #Foxp3 and #Treg functionality

010

Ruben Sebastian @rubensebas.bsky.social · 02/06/2025

BioNTech and Bristol Myers Squibb @bristolmyerssquibb.bsky.social enter global strategic #partnership to advance BNT327 (PD-L1 x VEGF-A bispecific #antibody) & #oncology leadership

000

Ruben Sebastian @rubensebas.bsky.social · 12/05/2025

Excited to be attending the 25th #BioEquityEurope in Bruges! Looking forward to reconnecting with fellow investors and #biotech colleagues across the life sciences ecosystem. Feel free to reach out if you'd like to connect during the event! #venturecapital #lifesciences

020

Ruben Sebastian @rubensebas.bsky.social · 30/04/2025

Happy to announce the launch of Adaptam Therapeutics, a new #biotech company pioneering #cancer immunotherapies by disrupting the immunosuppressive #myeloid TME through glyco-immune checkpoints to treat solid tumors I’m proud to be a founding member and to have led its incubation as Board Director

130

Ruben Sebastian @rubensebas.bsky.social · 13/03/2025

Fantastic evening supporting the first lecture organized by #CaixaResearchInstitute and catching up with many colleagues! It’s always inspiring to hear Gabi as he guides us through a ‘sweet’ path at the intersection of #glycobiology and #immunology with tremendous potential for human diseases.

040

Ruben Sebastian @rubensebas.bsky.social · 11/02/2025

The PCSK9-targeting epigenetic editor led to rapid and sustained 90% reduction of PCSK9 protein, resulting in a clinically meaningful 70% reduction in LDL-C in non-human primates

000

Ruben Sebastian @rubensebas.bsky.social · 11/02/2025

The human PCSK9-targeting #epigenetic editor packaged into an #LNP was able to reduce circulating PCSK9 protein 98% for a year after a *single administration* in a human PCSK9 transgenic mouse 🤯

100

Ruben Sebastian @rubensebas.bsky.social · 11/02/2025

ctDNA analysis revealed that a single dose of CAR-M induced robust *but transient* anti-tumor activity in patients with HER2 3+ tumors. Encouraging early data from this FIH, the field should build upon it!

110

Ruben Sebastian @rubensebas.bsky.social · 16/01/2025

$CARM has undergone a strategic restructuring, focusing on in vivo CAR-M generation (relying on its ongoing collaboration w Moderna to exploit mRNA/LNPs) and shifting toward #fibrosis, #oncology and #autoimmunity

000

Ruben Sebastian @rubensebas.bsky.social · 09/01/2025

Are we facing a new gold standard for intermediate stage #HCC? Lenvatinib (multi TKI) + pembrolizumab, combined with transarterial chemoembolisation (TACE), outperforms TACE alone (SoC) in PFS in a global, randomized, double-blind Phase 3 trial. www.thelancet.com/journals/lan...

010

Ruben Sebastian @rubensebas.bsky.social · 23/12/2024

Promising data in #IBD! Duvakitug, an anti-TL1A mAb, delivered positive Phase 2b results in moderate-to-severe ulcerative colitis and Crohn’s disease. Co-developed by Teva and Sanofi, a Phase 3 trial led by Sanofi is expected to kick off in 2025. ir.tevapharm.com/news-and-eve...

030

Ruben Sebastian @rubensebas.bsky.social · 29/11/2024

Delighted to have contributed to #CaixaImpulse Innovation one more edition, first delivering my annual #venturecapital 101 lecture and today participating in the investor's round table at the closing ceremony. It's always a blast to ignite the #entrepreneurial mindset in driven researchers!

050

Ruben Sebastian @rubensebas.bsky.social · 26/11/2024

$PSTX platform includes non-viral capabilities to design, develop and manufacture #allogeneic, T stem cell memory-rich #CART therapies. The acquisition will establish a new capability for Roche in allogeneic #celltherapy, with CAR-T programs in hemato malignancies, solid tumors & autoimmune diseases

030

Ruben Sebastian @rubensebas.bsky.social · 21/11/2024

Kate’s 'Directed Evolution of #AAV Capsid Leveraging In Vivo Expression of Transgene RNA' (DELIVER) platform has been used to evolve a novel class of liver de-targeted muscle-tropic capsids, which transduce skeletal muscle & cardiac tissue with potency & selectivity in vivo, while avoiding the liver

000

Ruben Sebastian @rubensebas.bsky.social · 17/11/2024

In its R&D day, BioNTech $BNTX shared its upcoming plans for BNT327 in lung, breast, GI and other tumor types, with short term readouts in SCLC and #TNBC, and in combo studies with a variety of different modalities (including #ADC and mRNA #vaccines)

100

Ruben Sebastian @rubensebas.bsky.social · 17/11/2024

BioNTech and Biotheus were already co-developing BNT327/PM8002 under a strategic #partnership established in Nov 2023 (over $1B). $BNTX is transitioning to a multi-product commercial #oncology company

100

Ruben Sebastian @rubensebas.bsky.social · 17/11/2024

Keytruda accounted for $25B of Merck’s $60B in revenue last year, when it became the world’s best-selling #medicine. But there is still room for improvement, as most patients don’t durably respond to ICBs. Keytruda is facing patent cliff in 2028, and $MRK will be pressed to replace lost revenues

100